GSK Chief Executive Emma Walmsley to Step Down After Eight Years at the Helm

Published: 29 September ‘2025. The English Chronicle Desk

In a surprising move, pharmaceutical giant GSK has confirmed that Emma Walmsley, its chief executive since 2017, will be stepping down from her role at the end of this year. Walmsley, who has guided the FTSE 100 company through nearly a decade of strategic transformation, will remain with the firm until her notice period concludes on 30 September 2026, ensuring a smooth transition to new leadership.

In a statement, Walmsley reflected on her tenure: “2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe this is the right moment for new leadership. As CEO, you hope to leave the company you love stronger than you found it and prepare for seamless succession. I’m proud to have done both – and to have created Haleon, a new world leader in consumer health. Today, GSK is a biopharma innovator, with far stronger momentum and prospects than nine years ago.”

Her successor will be Luke Miels, the company’s current chief commercial officer, who has been with GSK since 2017. Miels will take over the role of CEO following Walmsley’s departure, marking a significant leadership change in one of the United Kingdom’s largest pharmaceutical firms.

Walmsley’s eight-year tenure at GSK has been marked by significant corporate restructuring, most notably the demerger of the company’s consumer healthcare business, Haleon. This separation represented GSK’s largest corporate transformation in two decades and positioned the newly formed entity as a global leader in consumer health products. Under Walmsley, GSK has also strengthened its focus on specialty medicines and vaccines, improving its competitive positioning in the global pharmaceutical market.

Financially, Walmsley has been among the highest-paid executives in London, receiving a total package of £10.6 million last year, down from £12.7 million in 2023 due to lower performance-related bonuses. Her fixed pay has remained relatively stable at £1.6 million annually.

Sir Jonathan Symonds, chair of GSK, praised Walmsley for her transformative leadership, stating: “Emma Walmsley has delivered outstanding leadership in driving a strategic transformation of GSK, including the successful demerger of Haleon. The company today is very different from when she joined nine years ago and has a bright and ambitious future. Its performance is now anchored in a stronger portfolio balanced across specialty medicines and vaccines.”

GSK, headquartered in London, employs over 65,000 people worldwide and remains one of the largest companies listed on the London Stock Exchange, with a market capitalisation of approximately £60 billion. Walmsley’s departure comes at a challenging time for the pharmaceutical industry, which faces potential disruption from international trade tensions. Notably, former U.S. President Donald Trump has threatened to impose new tariffs on branded drugs, as well as trucks and kitchen cabinets, adding pressure to global pharmaceutical companies navigating complex supply chains.

As GSK prepares to enter a new phase under Miels’ leadership, the company will be closely watched by investors and industry analysts for its strategy in maintaining momentum in biopharma innovation, expanding vaccine and specialty medicine portfolios, and navigating the ongoing challenges posed by international trade policies. Walmsley’s tenure will be remembered as a period of bold restructuring, strategic growth, and industry leadership, with Haleon’s successful spin-off standing as a testament to her ambitious vision for the company.